Crispr Therapeutics AG vs Roblox Corp — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Roblox Corp trades at $48.09 (market cap $32.52B). The key difference: Roblox Corp is far larger — about 6.7× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Roblox Corp for 93 Days on average.
| CRSP | RBLX | |
|---|---|---|
Market Cap | $4.88B | $32.52B |
Volume | 2,861,747 | 14,552,045 |
Sector | Health | Technology |
52-Week High | $73.97 | $138.56 |
52-Week Low | $44.34 | $35.54 |
Typical Hold Time | 77 Days | 93 Days |
Enterprise Value | $3.30B | $31.34B |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Roblox (RBLX) trades at $45.53, down 1.9% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company continues to demonstrate strong revenue growth, reaching $4.89 billion in 2025, but remains unprofitable with a net income margin of -17.61%. Recent analyst downgrades from Jefferies highlight concerns about bookings growth, creating mixed sentiment around the stock's near-term prospects.
While Roblox shows impressive revenue expansion and strong cash flow generation, persistent losses and high valuation metrics present significant risks. The stock faces headwinds from technical weakness and analyst skepticism, though long-term growth potential in the gaming platform remains intact. Investors must weigh the company's growth trajectory against ongoing profitability challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →